49.65
-1.673(-3.26%)
Currency In USD
| Previous Close | 51.32 |
| Open | 50.95 |
| Day High | 51 |
| Day Low | 49.22 |
| 52-Week High | 51.86 |
| 52-Week Low | 21.72 |
| Volume | 1.82M |
| Average Volume | 2.89M |
| Market Cap | 9.49B |
| PE | -12.02 |
| EPS | -4.13 |
| Moving Average 50 Days | 44.78 |
| Moving Average 200 Days | 34.96 |
| Change | -1.67 |
If you invested $1000 in BridgeBio Pharma, Inc. (BBIO) since IPO date, it would be worth $1,802.07 as of August 18, 2025 at a share price of $49.647. Whereas If you bought $1000 worth of BridgeBio Pharma, Inc. (BBIO) shares 5 years ago, it would be worth $1,701.99 as of August 18, 2025 at a share price of $49.647.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Novel Human Genetics Evidence Confirms Estimates of Genetic Prevalence, Underdiagnosis, and Potentially Greater Symptom Burden of Gain-of-Function CASR Variants Associated with ADH1
GlobeNewswire Inc.
Jul 23, 2025 11:30 AM GMT
- By examining over 100 unique variants associated with the CASR gene causative of ADH1, the average frequency of gain-of-function CASR variants was ~3.7 per 100,000, closely aligned to previously published estimates1 (3.9 per 100,000), which equates
BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET
GlobeNewswire Inc.
Jul 22, 2025 11:30 AM GMT
PALO ALTO, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that it will release its second quarter
BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty
GlobeNewswire Inc.
Jun 30, 2025 11:30 AM GMT
BridgeBio has received a $300 million upfront payment, strengthening the Company’s balance sheet, and supporting the launch of Attruby® and ongoing late-stage pipeline programsTransaction monetizes 60% of BridgeBio’s European royalties on the first $